Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri

MRI Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00752778

Enrollment

Registered

2008-09-15

Start date

2008-12-31

Completion date

2011-03-31

Last updated

2012-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

MRI, PET scan

Brief summary

To evaluate the diagnosis value of MRI and positon emission tomography (PET) scan for studying macrophagic infiltration and other brain modification in multiple sclerosis (MS) patients treated with Natalizumab (Tysabri).

Interventions

OTHERpet-scan FDG-F18

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients diagnosed with MS * Treatment with Tysabri planned

Exclusion criteria

* Allergy to Tysabri or MRI contrast products * Pregnancy

Design outcomes

Primary

Measure	Time frame
Number of enhanced lesions on MRI before and after treatment. PET scan modification in brain (in enhanced lesions and in the whole brain).	At baseline and after 3 months of treatment.

Secondary

Measure	Time frame
Correlation with relapses.	During the 3 months of treatment and the 3 following months.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026